Atai Beckley N.V. (FRA:9VC)

Germany flag Germany · Delayed Price · Currency is EUR
3.878
+0.368 (10.48%)
Last updated: Dec 5, 2025, 9:25 AM CET
145.44%
Market Cap 1.37B
Revenue (ttm) 2.57M
Net Income (ttm) -131.42M
Shares Out n/a
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 2,577
Open 3.748
Previous Close 3.510
Day's Range 3.748 - 3.878
52-Week Range 1.021 - 5.980
Beta n/a
RSI 46.49
Earnings Date Nov 14, 2025

About Atai Beckley

Atai Beckley N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizoph... [Read more]

Industry Pharmaceutical Preparations
Founded 2018
Employees 54
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 9VC
Full Company Profile

Financial Performance

In 2024, Atai Beckley's revenue was $308,000, a decrease of -1.91% compared to the previous year's $314,000. Losses were -$149.27 million, 271.1% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.